Gene Therapy Promising for SCID Due to ADA Deficiency

TUESDAY, May 11, 2021 -- For patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID), gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news